TY - JOUR
T1 - A Randomized Controlled Trial of Individual Family Psychoeducational Psychotherapy and Omega-3 Fatty Acids in Youth with Subsyndromal Bipolar Disorder
AU - Fristad, Mary A.
AU - Young, Andrea S.
AU - Vesco, Anthony T.
AU - Nader, Elias S.
AU - Healy, K. Zachary
AU - Gardner, William
AU - Wolfson, Hannah L.
AU - Arnold, L. Eugene
N1 - Publisher Copyright:
© 2015 Mary Ann Liebert, Inc.
PY - 2015/12/1
Y1 - 2015/12/1
N2 - Objective: This pilot study evaluates efficacy of omega-3 fatty acid supplementation (ω3), individual family psychoeducational psychotherapy (IF-PEP), and their combination in youth with subsyndromal bipolar disorders (bipolar disorder not otherwise specified [BP-NOS], cyclothymic disorder [CYC]). Methods: This study was a 12 week, randomized trial of ω3 versus placebo and IF-PEP versus active monitoring (AM) using a 2 × 2 design (ω3 + PEP: n = 5; ω3 + AM: n = 5; placebo + PEP: n = 7; placebo + AM: n = 6). Twenty-three youth ages 7-14 with BP-NOS or CYC were recruited via community advertisements and clinician referrals. Participants could be taking stable medication for attention-deficit/hyperactivity disorder and sleep aids, but no other psychotropics. Independent evaluators assessed participants at screen, baseline, and 2, 4, 6, 9, and 12 weeks. Primary outcome measures were the Kiddie Schedule for Affective Disorders (K-SADS) Depression (KDRS) and Mania (KMRS) Rating Scales, Children's Depression Rating Scale-Revised (CDRS-R), and Young Mania Rating Scale (YMRS). ω3/placebo conditions were double-blind; independent evaluators were blind to psychotherapy condition. Results: Most participants (83%) completed the 12 week trial. Side effects were uncommon and mild. Intent-to-treat analyses indicated significant improvement in depressive symptoms (KDRS) for combined treatment relative to placebo and AM (p = 0.01, d = 1.70). Across groups, manic symptoms improved over time without significant treatment effects. Effect of IF-PEP on child depression compared with AM was medium (d = 0.63, CDRS-R) to large (d = 1.24, KDRS). Effect of ω3 on depression was medium (d = 0.48, KDRS). Conclusion: IF-PEP and ω3 are well tolerated and associated with improved mood symptoms among youth with BP-NOS and CYC.
AB - Objective: This pilot study evaluates efficacy of omega-3 fatty acid supplementation (ω3), individual family psychoeducational psychotherapy (IF-PEP), and their combination in youth with subsyndromal bipolar disorders (bipolar disorder not otherwise specified [BP-NOS], cyclothymic disorder [CYC]). Methods: This study was a 12 week, randomized trial of ω3 versus placebo and IF-PEP versus active monitoring (AM) using a 2 × 2 design (ω3 + PEP: n = 5; ω3 + AM: n = 5; placebo + PEP: n = 7; placebo + AM: n = 6). Twenty-three youth ages 7-14 with BP-NOS or CYC were recruited via community advertisements and clinician referrals. Participants could be taking stable medication for attention-deficit/hyperactivity disorder and sleep aids, but no other psychotropics. Independent evaluators assessed participants at screen, baseline, and 2, 4, 6, 9, and 12 weeks. Primary outcome measures were the Kiddie Schedule for Affective Disorders (K-SADS) Depression (KDRS) and Mania (KMRS) Rating Scales, Children's Depression Rating Scale-Revised (CDRS-R), and Young Mania Rating Scale (YMRS). ω3/placebo conditions were double-blind; independent evaluators were blind to psychotherapy condition. Results: Most participants (83%) completed the 12 week trial. Side effects were uncommon and mild. Intent-to-treat analyses indicated significant improvement in depressive symptoms (KDRS) for combined treatment relative to placebo and AM (p = 0.01, d = 1.70). Across groups, manic symptoms improved over time without significant treatment effects. Effect of IF-PEP on child depression compared with AM was medium (d = 0.63, CDRS-R) to large (d = 1.24, KDRS). Effect of ω3 on depression was medium (d = 0.48, KDRS). Conclusion: IF-PEP and ω3 are well tolerated and associated with improved mood symptoms among youth with BP-NOS and CYC.
UR - http://www.scopus.com/inward/record.url?scp=84951291487&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84951291487&partnerID=8YFLogxK
U2 - 10.1089/cap.2015.0132
DO - 10.1089/cap.2015.0132
M3 - Article
C2 - 26682997
AN - SCOPUS:84951291487
SN - 1044-5463
VL - 25
SP - 764
EP - 774
JO - Journal of child and adolescent psychopharmacology
JF - Journal of child and adolescent psychopharmacology
IS - 10
ER -